GlassScriptPhysician profile
Charles A Trout
NPI 1215929344
$5,148.37
in general payments reported to CMS, 2019-2025
36 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,647 · 2020: $950 · 2021: $1,751 · 2022: $801.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $882.15 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $500.31 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $425.73 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $398.30 | 2019-2022 | |
| Glaxosmithkline, LLC. | $387.43 | 2019-2022 | |
| Abbvie INC. | $343.50 | 2019-2022 | |
| Pfizer INC. | $268.55 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $243.20 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $180.82 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $148.42 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $127.89 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $114.55 | 2021 | |
| Lilly USA, LLC | $108.58 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $100.72 | 2019-2021 | |
| Eisai INC. | $91.94 | 2020-2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $87.21 | 2019-2021 | |
| Amgen INC. | $82.43 | 2019-2021 | |
| Currax Pharmaceuticals LLC | $81.09 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $77.22 | 2022 | |
| Abbott Laboratories | $76.45 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $56.64 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $54.63 | 2020-2022 | |
| Astellas Pharma US INC | $49.64 | 2021 | |
| Sanofi Pasteur INC. | $48.65 | 2020-2022 | |
| Esperion Therapeutics, INC. | $39.70 | 2021 | |
| Mannkind Corporation | $24.66 | 2019 | |
| Edwards Lifesciences Corporation | $18.15 | 2022 | |
| Allergan, INC. | $18.14 | 2019 | |
| Medtronic Minimed, INC. | $15.97 | 2019 | |
| Genentech USA, INC. | $15.49 | 2019 | |
| Biogen, INC. | $15.10 | 2019 | |
| Sunovion Pharmaceuticals INC. | $14.54 | 2022 | |
| Dexcom, INC. | $14.09 | 2022 | |
| Seqirus USA INC | $13.25 | 2020 | |
| Shire North American Group INC | $12.62 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $10.61 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Trout listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.